Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician

Overview of attention for article published in Current Rheumatology Reports, June 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet
policy: 2 policy sources

twitter: 4 X users

Readers on

mendeley: 125 Mendeley

Summary News Policy documents X

So far, Altmetric has seen 2 policy documents that reference this research output.

Switching From Reference to Biosimilar Etanercept for Patients with Plaque Psoriasis

Cited by Canadian Agency for Drugs and Technologies in Health on 17 Feb 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe

Cited by rijksoverheid.nl on 01 May 2018

rijksoverheid.nl is a searchable database of documents produced by the Dutch government.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.